Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of OPF-110 in Healthy Adult Participants
NCT07848334Phase 1Active, not recruiting
- Sponsor
- Otsuka Pharmaceutical Factory, Inc.
- Start
- Aug 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of OPF-110 in Malnutrition (2 arms), sponsored by Otsuka Pharmaceutical Factory, Inc. Primary endpoints: Number of Adverse Events and Number of Serious Adverse Events. Started Aug 2026; status: active, not recruiting.
02
Drugs
OPF-110
03
Conditions
Malnutrition
Beyond the preview
Go deeper on NCT07848334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07848334.